Opin vísindi

Generating real-world evidence on the quality use, benefits and safety of medicines in australia : History, challenges and a roadmap for the future

Show simple item record

dc.contributor.author Pearson, Sallie Anne
dc.contributor.author Pratt, Nicole
dc.contributor.author Costa, Juliana de Oliveira
dc.contributor.author Zoéga, Helga
dc.contributor.author Laba, Tracey Lea
dc.contributor.author Etherton-Beer, Christopher
dc.contributor.author Sanfilippo, Frank M.
dc.contributor.author Morgan, Alice
dc.contributor.author Ellett, Lisa Kalisch
dc.contributor.author Bruno, Claudia
dc.contributor.author Kelty, Erin
dc.contributor.author Ijzerman, Maarten
dc.contributor.author Preen, David B.
dc.contributor.author Vajdic, Claire M.
dc.contributor.author Henry, David
dc.date.accessioned 2022-03-19T01:03:31Z
dc.date.available 2022-03-19T01:03:31Z
dc.date.issued 2021-12-18
dc.identifier.citation Pearson , S A , Pratt , N , Costa , J D O , Zoéga , H , Laba , T L , Etherton-Beer , C , Sanfilippo , F M , Morgan , A , Ellett , L K , Bruno , C , Kelty , E , Ijzerman , M , Preen , D B , Vajdic , C M & Henry , D 2021 , ' Generating real-world evidence on the quality use, benefits and safety of medicines in australia : History, challenges and a roadmap for the future ' , International Journal of Environmental Research and Public Health , vol. 18 , no. 24 , 13345 . https://doi.org/10.3390/ijerph182413345
dc.identifier.issn 1661-7827
dc.identifier.other PURE: 44406321
dc.identifier.other PURE UUID: 29d67092-1604-45fa-b4d6-6f209ead0784
dc.identifier.other Scopus: 85121291562
dc.identifier.other unpaywall: 10.3390/ijerph182413345
dc.identifier.uri https://hdl.handle.net/20.500.11815/2961
dc.description Funding text 1 Funding: This review is supported by the National Health and Medical Research Council (NHMRC) Centre of Research Excellence in Medicines Intelligence (GNT1196900); H.Z. is supported by a UNSW Scientia Fellowship; E.K. is supported by an NHMRC Emerging Leader Fellowship (APP1172978); C.B. is supported by an Australian Government Research Training Program Scholarship. Funding text 2 Conflicts of Interest: C.E.B. is a member of the Pharmaceutical Benefits Advisory Committee (PBAC); S.P., N.P., T.L. and C.E.B. are members of the Drug-Utilization Sub-Committee of the PBAC; T.L. is a member of the Economics Sub-Committee of the PBAC; M.I. is a member of the Economics Sub-Committee of the MSAC; S.P. is a member of the National Data Advisory Council; C.M.V. is Deputy Chair of the NSW Population Health Service Research Ethics Committee; D.P. is a member of the Sax Institute Board. The views of authors expressed in this review article are their own and do not represent those of the aforementioned bodies. In 2020, the Centre for Big Data Research in Health received funding from AbbVie Australia to conduct post-market surveillance research. AbbVie did not have any knowledge of, or involvement in, this manuscript. Publisher Copyright: © 2021 by the authors. Li-censee MDPI, Basel, Switzerland.
dc.description.abstract Australia spends more than $20 billion annually on medicines, delivering significant health benefits for the population. However, inappropriate prescribing and medicine use also result in harm to individuals and populations, and waste of precious health resources. Medication data linked with other routine collections enable evidence generation in pharmacoepidemiology; the science of quantifying the use, effectiveness and safety of medicines in real-world clinical practice. This review details the history of medicines policy and data access in Australia, the strengths of existing data sources, and the infrastructure and governance enabling and impeding evidence generation in the field. Currently, substantial gaps persist with respect to cohesive, contemporary linked data sources supporting quality use of medicines, effectiveness and safety research; exemplified by Aus-tralia’s limited capacity to contribute to the global effort in real-world studies of vaccine and dis-ease-modifying treatments for COVID-19. We propose a roadmap to bolster the discipline, and population health more broadly, underpinned by a distinct capability governing and streamlining access to linked data assets for accredited researchers. Robust real-world evidence generation requires current data roadblocks to be remedied as a matter of urgency to deliver efficient and equitable health care and improve the health and well-being of all Australians.
dc.language.iso en
dc.relation.ispartofseries International Journal of Environmental Research and Public Health; 18(24)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Lýðheilsa
dc.subject Ástralía
dc.subject Ástralía
dc.subject Lyf
dc.subject Data linkage
dc.subject Health outcomes
dc.subject Medication data
dc.subject Medication safety
dc.subject Pharmacoepidemiology
dc.subject Prescribing
dc.subject Quality use of medicines
dc.subject Real-world data
dc.subject Real-world evidence
dc.subject Humans
dc.subject Forecasting
dc.subject COVID-19
dc.subject SARS-CoV-2
dc.subject Australia
dc.subject Public Health, Environmental and Occupational Health
dc.subject Pollution
dc.subject Health, Toxicology and Mutagenesis
dc.title Generating real-world evidence on the quality use, benefits and safety of medicines in australia : History, challenges and a roadmap for the future
dc.type /dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/systematicreview
dc.description.version Peer reviewed
dc.identifier.pmid 34948955
dc.identifier.doi https://doi.org/10.3390/ijerph182413345
dc.relation.url http://www.scopus.com/inward/record.url?scp=85121291562&partnerID=8YFLogxK
dc.contributor.department Faculty of Medicine

Files in this item

This item appears in the following Collection(s)

Show simple item record